CLAIMS

1. Use of a protein or polypeptide comprising a polypeptide that has at least 90 % sequence identity with the amino acid sequence SEQ ID NO: 1 in the manufacture of a medicament for treating and/or preventing thromboinflammation.

2. The use according to claim 1, wherein said protein or polypeptide comprises a polypeptide having the amino acid sequence SEQ ID NO: 1.

3. The use according to claim 1, wherein said protein or polypeptide comprises a polypeptide having the amino acid sequence SEQ ID NO: 2.

4. The use according to any one of claims 1-3, wherein said thromboinflammation is selected from the group comprising atherosclerosis, plaque rupture, devices-induced thromboinflammation, thrombosis induced by catheterism and/or stent positioning procedures, thrombosis induced by extracorporeal circulation, thrombus formation following cerebral injuries, coronary artery disease, acute myocardial infarction, cancer-associated thrombosis, metastasis-associated thrombosis, stroke-associated thrombosis, Behçet's disease (BD), antineutrophil cytoplasmic antibody-associated (ANCA) vasculitides, Takayasu arteritis, rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, familial Mediterranean fever, thromboangiitis obliterans (TAO), sepsis, inflammatory bowel diseases, heparin-induced thrombocytopenia, immunothrombosis, thrombosis associated with preeclampsia, thrombotic complication in cell and cell cluster transplantation and in whole organ transplantation or grafts, venous thromboembolism, aneurysms, and skeletal muscle ischemia-reperfusion syndrome.

5. The use according to claim 4, wherein said thromboinflammation is thrombus formation following cerebral injuries.

6. The use according to claim 4, wherein said thromboinflammation is stroke-associated thrombosis.

7. The use according to claim 4, wherein said thromboinflammation is acute myocardial infarction.

8. The use according to claim 4, wherein said thromboinflammation is thrombosis associated with preeclampsia.

9. The use according to claim 4, wherein said thromboinflammation is immunothrombosis.

10. The use according to claim 4, wherein said thromboinflammation is atherosclerosis.

11. The use according to claim 4, wherein said thromboinflammation is thrombosis induced by catheterism and/or stent positioning procedures.

12. The use according to claim 4, wherein said thromboinflammation is blood contacting medical devices-induced thromboinflammation.

13. The use according to claim 4, wherein said thromboinflammation is plaque rupture.

14. The use according to claim 4, wherein said thromboinflammation is thrombosis associated with the extracorporeal circulation.

15. Use of a pharmaceutical composition comprising a protein or polypeptide comprising a polypeptide that has at least 90 % sequence identity with the amino acid sequence SEQ ID NO: 1 and at least one pharmaceutically acceptable excipient in the manufacture of a medicament for treating and/or preventing thromboinflammation.